Back to news

Quanterix Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory

Business Wire•16/11/2026•13:30 ET
3

Key Highlights

  • ➤Quanterix signs exclusive distribution agreement with Sherman Abrams Laboratory
  • ➤LucentAD Complete expands blood-based Alzheimer’s testing access across New Jersey region
  • ➤Sherman Abrams will offer testing through its Metro NY/NJ referring-physician network
  • ➤Agreement targets earlier Alzheimer’s detection for at-risk patients lacking formal diagnoses

Expert Statements

Everett Cunningham, CEO of Quanterix

“Sherman Abrams Lab understands the patient's needs and shares our commitment to expanding access to advanced diagnostics. Access has been one of the biggest barriers standing between blood-based testing and the patients who need it. This partnership is intended to help close the gap and lead to earlier answers and better outcomes for patients and their families.”

Sal Prifitera, Executive Vice President and Chief Business Officer of Sherman Abrams Laboratory

“We are excited to partner with Quanterix to bring this innovative Alzheimer's blood testing technology to the physicians and patients we serve. This collaboration reflects our continued commitment to advancing diagnostic capabilities, improving access to cutting-edge testing, and helping physicians make more informed decisions for their patients.”

Quanterix Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory

New Distribution Agreement paves the way for expanded regional access to LucentAD® Complete

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in